Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.43 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | HCK | P08631 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430744 | 0.81 | EGFR (0.51) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6431200 | 0.79 | AURKB (0.52) | EGFRKDRLCKSRCPIK3CD | |
| SCHEMBL6431769 | 0.78 | CCR4 (0.46) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6430931 | 0.75 | SGK1 (0.48) | EGFRKDREIF2AK3SRCPIK3CD | |
| SCHEMBL6435165 | 0.75 | SRC (0.49) | EGFRKDRSRCPIK3CDABL1 | |
| SCHEMBL5823867 | 0.74 | KIT (0.46) | EGFRKDRSRCPIK3CDABL1 | |
| SCHEMBL5803301 | 0.74 | CCR4 (0.51) | EGFRKDREIF2AK3SRCPIK3CD | |
| SCHEMBL5822845 | 0.73 | CCR4 (0.47) | EGFRKDREIF2AK3SRCPIK3CD | |
| SCHEMBL6433439 | 0.73 | CCR4 (0.55) | EGFRKDRSRCPIK3CDABL1 | |
| SCHEMBL6430815 | 0.73 | CCR4 (0.57) | EGFRKDREIF2AK3SRCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885ERBB2 894/4885IGF1R 4007/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885ERBB2 529/4885IGF1R 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.